Some challenges with statistical inference in adaptive designs

Journal of Biopharmaceutical Statistics

Volumn 24, Issue 5, 2014, Pages 1059-1072

  Hung, H M James ^a   Wang, Sue Jane ^a   Yang, Peiling ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adaptive selection; Adaptive statistical information; Biomarker; Marker; Unweighted Z statistic; Weighted Z statistic.

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; ERROR; HUMAN; INFORMATION; MATHEMATICAL COMPUTING; POPULATION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STATISTICAL ANALYSIS; STUDY DESIGN; UNCERTAINTY; METHODOLOGY; OBSERVER VARIATION; PROCEDURES; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; OBSERVER VARIATION; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84905975687     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2014.925911     Document Type: Conference Paper

References (37)

1. Bauer, P., Köhne, K. (1994). Evaluations of experiments with adaptive interim analyses. Biometrics 50:1029-1041.
2. Bauer, P., König, F. (2006). The reassessment of trial perspectives from interim data-A critical view. Statistics in Medicine 25:23-36. (Pubitemid 43136947)
3. Brannath, W., Posch, M., Bauer, P. (2002). Recursive combination tests. Journal of the American Statistical Association 97:236-244.
4. Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M., Racine-Poon, A. (2009). Confirmatory Adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 28:1445-1463.
5. Branson, M., Brannah, W., Dunger-Baldauf, C., Bauer, P. (2005). Testing and estimation in flexible group sequential design with adaptive treatment selection. Statistics in Medicine 24:3697-3714. (Pubitemid 43115726)
6. Chen, Y. H., DeMets, D. L., Lan, K. K. (2004). Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine 2004; 23:1023-1038. (Pubitemid 38477065)
7. Chow, S. C., Chang, M. (2006). Adaptive Design Methods in Clinical Trials. New York, NY: Chapman and Hall/CRC Press, Taylor & Francis.
8. Cui, L., Hung, H. M. J., Wang, S. J. (1999). Modification of sample size in group sequential clinical trials. Biometrics 55:321-324.
9. Denne, J. S. (2001). Sample size recalculation using conditional power. Statistics in Medicine 20:2645-2660. (Pubitemid 32834374)
10. Emerson, S. S., Levin, G. P., Emerson, S.C. (2011). Comments on 'Adaptive increase in sample size when interim results are promising:a practical guide with examples.' Statistics in Medicine 30:3285-3301.
11. Food and Drug Administration.(2010). FDA draft guidance for industry: Adaptive design clinical trials for drugs and biologics. Available at www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ UCM201790.pdf (released for public comments February 25).
12. Gao, P., Ware, J. H., Mehta, C. R. (2008). Sample size re-estimation for adaptive sequential design in clinical trials. Journal of Biopharmaceutical Statistics 18:1184-1196.
13. Hung, H. M. J., O'Neill, R.,Wang, S. J., Lawrence, J. (2006). A regulatory view on adaptive/flexible clinical trial design (with rejoinder). Biometrical Journal 48: 565-573, 613-615.
14. Hung, H. M. J., Wang, S. J. (2012). Sample size adaptation in fixed-dose combination drug trial. Journal of Biopharmaceutical Statistics 22:679-686.
15. Hung, H. M. J., Wang, S. J., O'Neill, R. (2006). Methodological issues with adaptation of clinical trial design. Pharmaceutical Statistics 5:99-107. (Pubitemid 43891293)
16. Hung, H. M. J., Wang, S. J., O'Neill, R. (2011). Flexible design clinical trial methodology in regulatory applications. Statistics in Medicine 30:1519-1527.
17. König, F., Brannah,W., Bretz, F., Posch, M. (2008). Adaptive Dunnett tests for treatment selection. Statistics in Medicine 27:1612-1625 (Pubitemid 351566086)
18. Lan, K. K. G., Wittes, J. (1988). The B-value: Maryland tool for monitoring data. Biometrics 44:579-585.
19. Lawrence, J., Hung, H. M. J. (2003). Estimation and confidence intervals after adjusting the maximum information. Biometrical Journal 45:143-152. (Pubitemid 36419889)
20. Lehmacher, W., Wassmer, G. (1999). Adaptive sample size calculation in group sequential trials. Biometrics 55:1286-1290.
21. Liu, Q., Andersen, K. M. (2008). On adaptive extensions of group sequential trials for clinical investigations. Journal of the American Statistical Association 103:3267-3284.
22. Liu, Q., Proschan, M. A., Pledger, G W. (2002). A unified theory of two-stage adaptive designs. Journal of the American Statistical Association 97:1034-1041. (Pubitemid 36136563)
23. Mehta, C. R., Gao, P., Bhatt, D. L., Harrington, R. A., Skerjanec, S., Ware, J. H. (2009). Optimizing trial design: Sequential, adaptive, and enrichment strategies. Circulation 119:597-605.
24. Mehta, C. R., Pocock, S. J. (2011). Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine 30:3267-3284.
25. Müller, H. H., Shäfer, H. (2001). Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 57:886-891. (Pubitemid 32801186)
26. Posch, M., Bauer, P., Brannath, W. (2003). Issues in designing flexible trials. Statistics in Medicine 22:953-969. (Pubitemid 36322097)
27. Posch, M., Maurer,W., Bretz, F. (2010). Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. Pharmaceutical Statistics 10:96-104.
28. Proschan, M. A., Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics 51:1315-1324. (Pubitemid 26030176)
29. Shi,W. J. (2001). Comment on Type I error in sample size re-estimation based on observed treatment difference (p 497-513). Statistics in Medicine 20:515-518.
30. Shun, Z., Yuan, W., Brady, W. E., Hsu, H. (2001). Type I error in sample size re-estimations based on observed treatment difference. Statistics in Medicine 20:497-513. (Pubitemid 32166415)
31. Wang, S. J., Brannath, W., Brückner, M., Hung, H. M. J., Koch, A. (2013). Unblinded adaptive information design Based on clinical endpoint or biomarker. Statistics in Biopharmaceutical Research 5:293-310.
32. Wang, S. J., Hung, H. M. J. (2013). Adaptive enrichment with subpopulation selection at interim: methodologies, applications and design considerations. Contemporary Clinical Trials 36:673-681.
33. Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51:358-374.
34. Wang, S. J., Hung, H. M. J., O'Neill, R. (2010). Adaptive design clinical trials in CNS drug development. European Neuropsychopharmacology Journal 21:159-166.
35. Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2010). Impacts of Type I error rate with inappropriate use of learn for confirm in adaptive designs. Biometrical Journal 52:798-810.
36. Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2012). Paradigms for adaptive statistical information designs: practical experiences and strategies. Statistics in Medicine 31:3011-3023.
37. Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227-224.